ArticleTherapeutic advances in medical oncology2025

TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with

Daniel Shao-Weng Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.